The Co-CEOs of Summit Therapeutics discuss the ivonescimab vs Keytruda data that was presented at the 2024 World Conference on Lung Cancer

blonca9
Sep 10, 2024
1 min read

Bob Duggan and Maky Zanganeh answer questions relating to China derived data, designing U.S. studies, how to scale the development of the drug, and more.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

The Co-CEOs of Summit Therapeutics discuss the ivonescimab vs Keytruda data that was presented at the 2024 World Conference on Lung Cancer

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight